The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve System to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve System can more efficiently decongest ADHF patients in comparison to Control Therapy.
The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve System to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve System can more efficiently decongest ADHF patients in comparison to Control Therapy.
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
-
University of California Irvine, Irvine, California, United States, 92697
Trinity Health Ann Arbor Hospital, Ann Arbor, Michigan, United States, 48197
St. Louis VA, St. Louis, Missouri, United States, 63130
Washington University, St. Louis, Missouri, United States, 63130
Duke University, Durham, North Carolina, United States, 27710
Moses H. Cone Memorial Hospital, Greensboro, North Carolina, United States, 27401
Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States, 27157
Lindner Center at Christ Hospital, Cincinnati, Ohio, United States, 45219
Ohio State University Hospital, Columbus, Ohio, United States, 43210
Prisma Health Greenville Memorial Hospital, Greenville, South Carolina, United States, 29605
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
22 Years to
ALL
No
Reprieve Cardiovascular, Inc,
Javed Butler, MD, MPH, MBA, PRINCIPAL_INVESTIGATOR, Baylor Scott and White Health
2027-12